Education
About Us
Working with TipRanks
Follow Us
Shattuck Labs (STTK)
NASDAQ:STTK
STTK Analyst Ratings
Moderate Buy
2 Buy
3 Hold
0 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
STTK Stock 12 Month Forecast
Average Price Target
$1.50
▲(51.52% Upside)
| Highest Price Target$2.00 | Average Price Target$1.50 | Lowest Price Target$1.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
TR | OpenAI - 4o
$1
Hold
1.01%
Upside
Reiterated
08/27/25
H.C. Wainwright
―
Hold
―
Reiterated
08/22/25
Leerink Partners
$4→$2
Buy
102.02%
Upside
Reiterated
08/18/25
TD Cowen
―
Buy
―
Reiterated
08/14/25
Promising Financial Position and SL-325 Potential Drive Buy Rating for Shattuck LabsWe think these preclinical data are encouraging and provide some evidence that '325 and DR3 targeting will prove clinically superior to leading TL1A approaches. Q8W maintenance dosing would also prove competitive with leading IBD agents such as Entyvio if it can be established. Management also indicates that its preclinical data suggests '325 has much reduced immunogenecity relative to leading TL1A antibodies. They are hopeful this will be confirmed in the clinic and also result in more consistent pathway suppression across patients and also aide in driving improved clinical outcomes. We look forward to the initial Phase I data expected to be presented in 2026.Source: Shattuck Labs MARC FRAHM, PH.D.
Needham
―
Hold
―
Reiterated
08/14/25
Citi
$2
Hold
102.02%
Upside
Downgraded
10/02/24
Evercore ISI
―
Buy
―
Assigned
10/02/24
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
TR | OpenAI - 4o
$1
Hold
1.01%
Upside
Reiterated
08/27/25
H.C. Wainwright
―
Hold
―
Reiterated
08/22/25
Leerink Partners
$4→$2
Buy
102.02%
Upside
Reiterated
08/18/25
TD Cowen
―
Buy
―
Reiterated
08/14/25
Promising Financial Position and SL-325 Potential Drive Buy Rating for Shattuck LabsWe think these preclinical data are encouraging and provide some evidence that '325 and DR3 targeting will prove clinically superior to leading TL1A approaches. Q8W maintenance dosing would also prove competitive with leading IBD agents such as Entyvio if it can be established. Management also indicates that its preclinical data suggests '325 has much reduced immunogenecity relative to leading TL1A antibodies. They are hopeful this will be confirmed in the clinic and also result in more consistent pathway suppression across patients and also aide in driving improved clinical outcomes. We look forward to the initial Phase I data expected to be presented in 2026.Source: Shattuck Labs MARC FRAHM, PH.D.
Needham
―
Hold
―
Reiterated
08/14/25
Citi
$2
Hold
102.02%
Upside
Downgraded
10/02/24
Evercore ISI
―
Buy
―
Assigned
10/02/24
Best Analysts Covering Shattuck Labs
1 Month
xxx
Success Rate
3/10 ratings generated profit
Average Return
-5.95%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 30.00% of your transactions generating a profit, with an average return of -5.95% per trade.
3 Months
xxx
Success Rate
4/10 ratings generated profit
Average Return
+24.94%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 40.00% of your transactions generating a profit, with an average return of +24.94% per trade.
1 Year
Success Rate
1/10 ratings generated profit
Average Return
-40.72%
reiterated a buy rating 16 days ago
Copying Marc Frahm's trades and holding each position for 1 Year would result in 10.00% of your transactions generating a profit, with an average return of -40.72% per trade.
2 Years
xxx
Success Rate
1/10 ratings generated profit
Average Return
-47.71%
reiterated a xxx
rating 16 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 10.00% of your transactions generating a profit, with an average return of -47.71% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
STTK Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
3
1
1
1
Buy
1
2
1
1
1
Hold
5
7
9
11
16
Sell
1
1
1
0
0
Strong Sell
0
0
0
0
0
total
9
13
12
13
18
Each month's total comprises the sum of three months' worth of ratings.
STTK Financial Forecast
STTK Stock Forecast FAQ
What is STTK’s average 12-month price target, according to analysts?
Based on analyst ratings, Shattuck Labs’s 12-month average price target is 1.50.
What is STTK’s upside potential, based on the analysts’ average price target?
Shattuck Labs has 51.52% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is STTK a Buy, Sell or Hold?
Shattuck Labs has a consensus rating of Moderate Buy which is based on 2 buy ratings, 3 hold ratings and 0 sell ratings.
What is Shattuck Labs’s price target?
The average price target for Shattuck Labs is 1.50. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $2.00 ,the lowest forecast is $1.00. The average price target represents 51.52% Increase from the current price of $0.99.
The highest analyst price target is $2.00 ,the lowest forecast is $1.00. The average price target represents 51.52% Increase from the current price of $0.99.
What do analysts say about Shattuck Labs?
Shattuck Labs’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 5 Wall Streets Analysts.
How can I buy shares of STTK?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.